Shares of BioCryst Pharmaceuticals, Inc. (BCRX) soared 10% in pre-market trading on Monday after the company raised its full-year guidance and reported first quarter (Q1) earnings above Wall Street expectations.
The firm reported total revenue of $145.5 million, compared to $92.8 million in the first quarter of 2024, owing to an increase in revenue from Orladeyo. The Q1 revenue beat an analyst estimate of $127.79 million, as per Finchat data.
Orladeyo is a prescription medicine used to prevent attacks of hereditary angioedema (HAE), a rare, genetic condition causing recurrent episodes of swelling in various parts of the body, in adults and children 12 years of age and older.
Orladeyo's net revenue in the first quarter of 2025 was $134.2 million, a 51% jump from the previous year.
Net income for the first quarter was $32,000 or $0 per share, compared to a net loss of $35.4 million, or $0.17 per share, for the first quarter of 2024. Analysts expected the company to report a loss of $0.05 per share.
The company has already submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to expand the Orladeyo label to children with HAE aged 2 to 11 using an oral granule formulation.
The company also increased its full-year outlook. It now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
The company also expects to deliver net income and positive cash flows for the full year 2025, earlier than its previous outlook for achieving it in 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.